Banque Cantonale Vaudoise Increases Stock Holdings in Cencora, Inc. (NYSE:COR)

Banque Cantonale Vaudoise lifted its position in Cencora, Inc. (NYSE:COR - Free Report) by 11.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,024 shares of the company's stock after acquiring an additional 2,278 shares during the period. Banque Cantonale Vaudoise's holdings in Cencora were worth $5,182,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. New Millennium Group LLC purchased a new position in Cencora during the second quarter valued at $26,000. TFO Wealth Partners LLC bought a new stake in Cencora during the first quarter worth about $30,000. MFA Wealth Advisors LLC purchased a new stake in Cencora in the second quarter worth about $30,000. Concord Wealth Partners bought a new position in shares of Cencora during the third quarter valued at approximately $30,000. Finally, LRI Investments LLC bought a new position in shares of Cencora during the first quarter valued at $31,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Price Performance

COR stock traded down $1.90 during mid-day trading on Tuesday, hitting $240.97. The company had a trading volume of 820,246 shares, compared to its average volume of 1,406,672. The company has a 50-day moving average price of $232.75 and a 200 day moving average price of $231.17. Cencora, Inc. has a 12-month low of $194.56 and a 12-month high of $251.56. The company has a market capitalization of $47.48 billion, a price-to-earnings ratio of 32.09, a P/E/G ratio of 1.60 and a beta of 0.44. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be paid a $0.55 dividend. This is an increase from Cencora's previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. Cencora's payout ratio is presently 29.29%.

Analyst Upgrades and Downgrades

Several brokerages have commented on COR. Barclays increased their target price on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Bank of America restated a "neutral" rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Wells Fargo & Company boosted their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a report on Thursday, August 1st. JPMorgan Chase & Co. raised their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a report on Wednesday, August 21st. Finally, Leerink Partners decreased their target price on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research note on Monday, October 7th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and an average price target of $271.20.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the company's stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company's stock, valued at $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 15.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.